Thioether Patents (Class 514/712)
-
Publication number: 20100204338Abstract: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine.Type: ApplicationFiled: April 14, 2008Publication date: August 12, 2010Applicant: Southern Research InstituteInventors: Zhican QU, Anshu Mittal ROY, Subramaniam ANANTHAN
-
Patent number: 7763662Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.Type: GrantFiled: December 7, 2004Date of Patent: July 27, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 7759399Abstract: A compound comprising a cyclopentanone, cyclopentenone, cyclohexanone or cyclohexenone group, wherein a first ring carbon atom carries an —SR substituent, R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group that, optionally, includes at least one heteroatom in its carbon skeleton, the remaining available ring carbon atoms are optionally substituted, and said compound either: —(a) is more soluble in water at a temperature of 20-40° C.; (b) is less lipophilic; and/or, (c) has a greater therapeutic index; or; (d) is less soluble in water at a temperature of 20-40° C.; (e) is more lipophilic; and/or, (f) has a greater therapeutic index; than an equivalent cyclohex-2-en-1-one or cyclopent-2-en-1-one derivative in which a hydrogen atom replaces said —SR group.Type: GrantFiled: September 27, 2004Date of Patent: July 20, 2010Assignee: Crawford Healthcare Holdings LimitedInventors: Stanley Michael Roberts, Maria Gabriella Santoro, Vasudev Jadhav, Alan Michael Happe, Paul Evans, Nicolette Christa Ross, Timothy James Snape
-
Publication number: 20100158974Abstract: The present invention relates to an implant or part thereof coated with a wax or a resin. Especially, the present invention relates to an implant or part thereof coated with shellac.Type: ApplicationFiled: October 19, 2007Publication date: June 24, 2010Inventors: Albert Schömig, Rainer Wessely, Kastrati Adnan, Anna Wieczorek
-
Publication number: 20100160434Abstract: There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C3-C10 alkenyl group optionally substituted with at least one halogen atom, a C3-C10 alkynyl group optionally substituted with at least one halogen atom, or the like, R2 represents a cyano group or the like, R3 represents a hydrogen atom, a halogen atom or a C1-C4 alkyl group, R4 represents a C1-C5 fluoroalkyl group, and n represents 0, 1 or 2.Type: ApplicationFiled: May 16, 2008Publication date: June 24, 2010Inventor: Hiroyuki Miyazaki
-
Publication number: 20100120745Abstract: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadine, Perphenazine, Bithionol, and Clomipramine.Type: ApplicationFiled: October 9, 2009Publication date: May 13, 2010Applicant: Southern Research InstituteInventors: Zhican Qu, Anshu M. Roy, Subramaniam Ananthan
-
Patent number: 7713939Abstract: The present invention provides illudin analogs of the general formula (I): where R1 is (CH2)n—X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or cyclo(C3-C6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R2 is absent; or R1 and R2 together comprise a 5-7 membered cyclic ring; R3 is (C1-C4)alkyl or H; R4 is H, SCH2CO2(C1-C4)alkyl, O—(C5-C12)aryl or —S—(C5-C12)aryl; R5 is H, OH or absent; R6 is (C1-C4)alkyl or absent; R7 is OH or OSi((C1-C4)alkyl)3; or R6 and R7 together are ethylenedioxy; R8 is optionally substituted (C1-C4)alkyl; and the bonds represented by ----- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).Type: GrantFiled: December 12, 2007Date of Patent: May 11, 2010Assignee: The Regents of The University of CaliforniaInventors: Trevor C. McMorris, Michael J. Kelner
-
Patent number: 7700657Abstract: Novel vitamin D analogs, markedly active in the fields of cell proliferation and differentiation, are selected from among (4E,6E)-7-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl}-3-ethylnona-4,6-dien-3-ol, (E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, (3E,5E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)-phenyl]-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, (E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)ethyl]phenyl}-1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, and (3E,5E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, and the geometric isomers thereof and these compounds in which one or more of the hydroxyl functions are protected by a protective group —(C?O)—R, in which R is a linear or branched alkyl radical having from 1 to 6 carbon atoms, an aryl radical having from 6 to 10 carbon atoms, or an aralkyl radical having from 7 to 11 carbon atoms, the aryl radical or the aralkyl radical optionalType: GrantFiled: November 24, 2003Date of Patent: April 20, 2010Assignee: Galderma Research & DevelopmentInventor: Jean-Michel Bernardon
-
Publication number: 20100074972Abstract: The present invention is directed to methods and compositions for the prevention of citrus greening disease. In one embodiment, there is provided a method for repelling or killing insect vectors of citrus greening disease comprising exposing the vectors to an effective amount of at least one volatile compound set forth in Tables 1 and 2 herein. In one embodiment, the volatile compound is dimethyl disulfide.Type: ApplicationFiled: August 25, 2009Publication date: March 25, 2010Inventors: Russell L. Rouseff, Lukasz L. Stelinski
-
Patent number: 7666900Abstract: To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.Type: GrantFiled: December 22, 2004Date of Patent: February 23, 2010Assignee: Hykes Laboratories LLCInventors: Shinji Yokoyama, Maki Tsujita, Reijiro Arakawa, Tomoji Aotsuka
-
Publication number: 20090317500Abstract: A pesticide or repellent comprising a liquid concentrate obtained from garlic juice by the removal of water from the juice.Type: ApplicationFiled: April 10, 2006Publication date: December 24, 2009Applicant: ECOSPRAY LIMITEDInventors: David Sadler-Bridge, Murree Groom
-
Publication number: 20090192212Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.Type: ApplicationFiled: February 23, 2009Publication date: July 30, 2009Applicant: Encore Health, LLCInventors: William Garner, Margaret Garner, Ronald D. Blum
-
Publication number: 20090062285Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.Type: ApplicationFiled: July 14, 2008Publication date: March 5, 2009Applicant: National Sun Yat-Sen UniversityInventors: Jyh-Horng Sheu, Chih-Hua Chao, Zhi-Hong Wen
-
Publication number: 20090004240Abstract: The present disclosure relates to implants with a biocompatible coating having antithrombogenic properties and which also contains a pharmacologically active agent, as well as a process for their production.Type: ApplicationFiled: April 29, 2008Publication date: January 1, 2009Applicant: CeloNova BioSciences, Inc.Inventors: Olaf Fritz, Ulf Fritz, Stefan Nagel, Michael Boxberger
-
Publication number: 20080280979Abstract: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof.Type: ApplicationFiled: March 26, 2008Publication date: November 13, 2008Inventor: Robert A.D. Scott
-
Publication number: 20080280815Abstract: The present invention relates to a method for lowering serum lipids, eg. triglycerides and/or cholesterol in a subject comprising administering a GLP-1 agonist to said subject.Type: ApplicationFiled: August 22, 2007Publication date: November 13, 2008Applicant: Novo Nordisk A/SInventors: Liselotte Bjerre Knudsen, Johan Selmer, Jeppe Sturise, Philip Just Larsen
-
Publication number: 20080280985Abstract: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a compound including an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer includes two groups selected from selenium, sulfur, S(O) and S(O)2 and may include an alkylene, alkenylene, cycloalkylene or arylene moiety between the selenium, sulfur, S(O) or S(O)2 groups, or a pharmaceutically acceptable salt or derivative thereof.Type: ApplicationFiled: March 26, 2008Publication date: November 13, 2008Inventor: Robert A. D. Scott
-
Publication number: 20080254140Abstract: Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals, inducers of nitric oxide production, anti-inflammatory agents, and negatively-charged phospholipids. Such combination methods may be used as single or multiple administration therapies, or in combination with other agents or therapies.Type: ApplicationFiled: August 18, 2005Publication date: October 16, 2008Inventors: Kenneth Widder, Jay Lichter
-
Publication number: 20080221109Abstract: The invention relates to the use of thioether derivatives of formula (I) wherein: R1 is an unsubstituted or substituted (C1-C6) alkyl, A is a divalent unit taken from the group CO, CR3(OR4), CR3(O—CO—R4), CR3(COOR4), C(?CR3R4), C(?CR3R4), C(?CR3—COOR4), C(?CR3—CN); X is an unsubstituted or substituted (C1-C3) alkylen, R2 is an unsubstituted or substituted (C1-C10)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkenyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (C3-C7)cycloalkenyl-(C1-C6)alkyl, (C2-C10)alkenyl, (C2-C10)alkinyl, (C6-C12)-aryl, heteroaryl, heterocyclyl, (C6-C12)-aryl-(C1-C3)alkyl, heteroaryl-(C1-C3)alkyl or heterocyclyl-(C1-C3) alkyl residue and wherein R1, X and A may form a 3 to 10 membered cycloalkyl ring or a pesticidally acceptable salt thereof, for the control of pests, for controlling pests.Type: ApplicationFiled: July 25, 2007Publication date: September 11, 2008Inventors: Stefan Schnatterer, Uwe Doeller, Michael Maier, Friederike Petry, Werner Knauf, Karl Seeger
-
Patent number: 7375252Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.Type: GrantFiled: April 2, 2002Date of Patent: May 20, 2008Assignee: AtheroGenics, Inc.Inventor: Charles Q. Meng
-
Publication number: 20080102034Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.Type: ApplicationFiled: June 14, 2007Publication date: May 1, 2008Inventors: Ulrich SPECK, Bruno Scheller
-
Publication number: 20080102033Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.Type: ApplicationFiled: June 14, 2007Publication date: May 1, 2008Inventors: Ulrich SPECK, Bruno Scheller
-
Patent number: 7361684Abstract: Transgenic animals that do not express functional SR-BI and ApoE develop severe atherosclerosis, by age four weeks in transgenic mice. Moreover, these animals exhibit progressive heart dysfunction by as early as age four weeks, and die by age nine weeks. This animal model has now been demonstrated to be useful as a screen for compounds which alleviate the symptoms of atherosclerosis and heart disease. Animals (Apo E?/? SR-BI+/?) were fed PROBUCOL beginning at the time of mating. Offspring are weaned at three weeks and fed PROBUCOL. In contrast to animals (Apo E?/? SR-BI?/?) not fed PROBUCOL, 50% of whom are dead at six weeks, all animals (Apo E?/? SR-BI?/?) on PROBUCOL have a normal phenotype (MRI of heart function, ECG, echocardiogram, histology) at six weeks. At seven to eight months, there is evidence of atherosclerosis and some myocardial infarction. This demonstrates that the compound has a preventative action. Animals who are taken off of the PROBUCOL all die within ten to twelve weeks.Type: GrantFiled: May 16, 2002Date of Patent: April 22, 2008Assignee: Massachusetts Institute of TechnologyInventors: Monty Krieger, Anne Braun, Helena E. Miettinen
-
Patent number: 7351745Abstract: The present invention relates to compositions and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and/or aesthetic appearance of skin.Type: GrantFiled: December 22, 2004Date of Patent: April 1, 2008Assignee: Avon Products, IncInventors: Laurence Dryer, Dmitri Ptchelintsev
-
Publication number: 20080019957Abstract: A method of treating skin changes and conditions in human skin including applying a topical preparation that includes an active agent including probucol, a derivative of probucol or a combination of probucol and a derivative of probucol.Type: ApplicationFiled: July 20, 2007Publication date: January 24, 2008Inventors: Birgit Neudecker, Falko Diedrich, Eberhard Wieland
-
Patent number: 7276631Abstract: The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.Type: GrantFiled: July 18, 2005Date of Patent: October 2, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Yong-Jin Wu, Huan He
-
Patent number: 7135550Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.Type: GrantFiled: September 3, 2002Date of Patent: November 14, 2006Assignees: GPC Biotech Inc., GPC Biotech AGInventors: Jon H. Come, Frank Becker, Nikolai A. Kley, Christoph Reichel
-
Patent number: 7119123Abstract: Antimicrobially active 4-methyl-4-aryl-2-pentanols of the Formula 1 below, methods for the preparation of these compounds and their use as antimicrobial active compounds are described. Surprisingly, compounds of the Formula 1 for which: R=hydrogen, hydroxyl, alkoxy group with up to 10 C atoms, straight-chain or branched, saturated or unsaturated alkyl with up to 10 C atoms, alkylthioether group with up to 10 C atoms, the alkylthioether group being bonded to the aromatic ring via a thioether bridge, fluorine, chlorine, bromine, iodine, or alkyl with up to 10 C atoms that is interrupted by one or more oxygen and/or sulphur atoms, have proved to be antimicrobially active.Type: GrantFiled: March 3, 2004Date of Patent: October 10, 2006Assignee: Symrise GmbH & Co. KGInventors: Gerhard Schmaus, Holger Joppe
-
Patent number: 6930125Abstract: The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.Type: GrantFiled: January 12, 2001Date of Patent: August 16, 2005Inventors: John F. Hunt, Benjamin M. Gaston
-
Patent number: 6878700Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.Type: GrantFiled: March 31, 2000Date of Patent: April 12, 2005Assignee: Abbott LaboratoriesInventors: James Link, Gang Liu, ZhongHua Pei, Tom von Geldern, Martin Winn, Zhili Xin, Steven A. Boyd, Gui-Dong Zhu, Jennifer C. Freeman, Indrani W. Gunawardana, Michael A. Staeger, Hwan-Soo Jae, John K. Lynch, Sheldon Wang
-
Patent number: 6867203Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.Type: GrantFiled: December 1, 2003Date of Patent: March 15, 2005Assignee: Abbott LaboratoriesInventor: Indrani W. Gunawardana
-
Publication number: 20040266886Abstract: A cosmetic and/or pharmaceutical composition containing: (a) a glycerol monocaprylate; (b) a fatty alcohol; (c) optionally, a surfactant selected from the group consisting of an anionic surfactant, a nonionic surfactant, a cationic surfactant, an amphoteric surfactant, a zwitterionic surfactant, and mixtures thereof; and (d) optionally, water.Type: ApplicationFiled: April 8, 2004Publication date: December 30, 2004Inventors: Werner Seipel, Daniela Prinz, Lars Zander, Dagmar Goebels
-
Patent number: 6812257Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.Type: GrantFiled: October 27, 2003Date of Patent: November 2, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Publication number: 20040167229Abstract: Disclosed are methods of lowering plasma CRP levels, reducing systemic inflammation, and inhibiting proinflammatory cytokine induced CRP production by administering an effective amount of a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of the substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl or a pharmaceutical composition comprising a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl.Type: ApplicationFiled: November 13, 2003Publication date: August 26, 2004Inventors: Rebecca Bakker-Arkema, Ok Hwang, Sotirios Karathanasis, Diane MacDougall
-
Publication number: 20040138147Abstract: The use of compounds of the formula 1Type: ApplicationFiled: December 23, 2003Publication date: July 15, 2004Applicant: Atherogenics, Inc.Inventors: Mitchell Glass, Patricia K. Somers, David B. Edwards
-
Publication number: 20040029839Abstract: Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: 1Type: ApplicationFiled: February 3, 2003Publication date: February 12, 2004Inventors: Christophe Boulle, Maria Dalko, Jean-Luc Leveque, Lucie Simonetti
-
Patent number: 6689922Abstract: The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.Type: GrantFiled: July 26, 2001Date of Patent: February 10, 2004Assignee: Galderma Research & Development S.N.C.Inventor: Jean-Michel Bernardon
-
Publication number: 20030171441Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy.Type: ApplicationFiled: March 14, 2002Publication date: September 11, 2003Inventor: Johannes Servatius Leonardus Maria Nottet
-
Patent number: 6608061Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar1—S—R1—S—Ar2 wherein R1 represents a nonmetal bridging group; Ar1 and Ar2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.Type: GrantFiled: February 14, 2000Date of Patent: August 19, 2003Assignees: Kyoma Hakko Kogyo Co., Ltd., Fuji Photo Film Co., Ltd.Inventors: Yoshiyuki Yonetani, Takeshi Takahashi, Yuko Kanda, Tamio Mizukami, Tatsuya Tamaoki, Shun-ichi Ikeda, Masanobu Takashima, Naoki Asanuma, Tadashi Inaba, Hiroshi Takeuchi, Hiroshi Kawamoto, Yoshihisa Tsukada, Masato Satomura, Hiroshi Kitaguchi
-
Publication number: 20030153536Abstract: The use of compounds of the formula 1Type: ApplicationFiled: October 25, 2002Publication date: August 14, 2003Inventors: Mitchell Glass, Patricia K. Somers, David B. Edwards
-
Patent number: 6602914Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.Type: GrantFiled: April 2, 2002Date of Patent: August 5, 2003Assignee: AtheroGenics, Inc.Inventor: Charles Q. Meng
-
Publication number: 20030105078Abstract: The invention relates to novel diphenyl derivatives, to processes for their preparation and to their use in medicaments.Type: ApplicationFiled: February 26, 2002Publication date: June 5, 2003Inventors: Helmut Haning, Michael Woltering, Gunter Schmidt, Christiane Faeste, Hilmar Bischoff, Axel Kretschmer, Verena Vohringer, Peter Ellinghaus
-
Publication number: 20030018070Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:Type: ApplicationFiled: February 14, 2000Publication date: January 23, 2003Inventors: YOSHIYUKI YONETANI, TAKESHI TAKAHASHI, YUKO KANDA, TAMIO MIZUKAMI, TATSUYA TAMAOKI, SHUN-ICHI IKEDA, MASANOBU TAKASHIMA, NAOKI ASANUMA, TADASHI INABA, HIROSHI TAKEUCHI, HIROSHI KAWAMOTO, YOSHIHISA TSUKADA, MASATO SATOMURA, HIROSHI KITAGUCHI
-
Publication number: 20030012803Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): 1Type: ApplicationFiled: July 11, 2002Publication date: January 16, 2003Inventors: Philippe Diaz, Jean-Michel Bernardon
-
Patent number: 6500416Abstract: There are described a flowable composition for controlling harmful insects and representatives of the order Acarina, comprising at least one pesticidally active compound, one or more signal substances selected from the group consisting of pheromones, kairomones and attractants, a UV absorber or a UV absorber mixture and, if appropriate, one or more additives selected from the group consisting of viscosity-regulating thickeners, fillers, solvents and other formulation auxiliaries, which composition comprises 40 to 98% by weight of the UV absorber or the UV absorber mixture, 0.01 to 30% by weight of one or more signal substance(s) and 0.1 to 20% by weight of one or more pesticidally active compound(s) of the formulae (I) to (V) as specified, and a method of controlling harmful insects and representatives of the order Acarina using this composition.Type: GrantFiled: February 22, 2001Date of Patent: December 31, 2002Assignee: Syngenta Crop Protection, Inc.Inventors: Dieter Hofer, Max Angst, Pierre-Joseph Charmillot
-
Patent number: 6498196Abstract: The present invention relates to novel thio-aminotetralin compounds of the formula (I) wherein Z, X, R1, R2, R3, R4, R5, and R6 are defined herein. The compounds are useful in pain management.Type: GrantFiled: December 14, 1999Date of Patent: December 24, 2002Inventors: Edward Roberts, Tiechao Li, Dilip Dixit, Krzysztof Bednarski, Dick Storer, Wuyi Wang
-
Publication number: 20020193446Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.Type: ApplicationFiled: April 2, 2002Publication date: December 19, 2002Inventor: Charles Q. Meng
-
Patent number: 6495152Abstract: A class of biopolymer including sulfur in the form of a thioester in the polymer backbone or a thioether in the polymer side chains has been developed. These are preferably produced by fermentation of bacteria with appropriate sulfur containing substrates, which are incorporated by a broad spectrum polyhydroxyalkanoate (“PHA”) polymerase. The sulfur-containing PHAs allow various applications and uses in industry. Representative embodiments of the applications of the sulfur-containing PHAs include their uses in the packaging industry, medicine, pharmacy, agriculture or food industry, as active agents or as coatings, packaging, or carriers.Type: GrantFiled: August 17, 2001Date of Patent: December 17, 2002Assignees: Tepha, Inc., Metabolix, Inc.Inventors: Alexander Steinbuchel, Tina Lütke-Eversloh, Christian Ewering
-
Publication number: 20020169215Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.Type: ApplicationFiled: April 2, 2002Publication date: November 14, 2002Inventor: Charles Q. Meng
-
Patent number: RE39197Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.Type: GrantFiled: August 29, 2002Date of Patent: July 18, 2006Assignee: Abbott LaboratoriesInventors: James T. Link, Gang Liu, Zhonghua Pei, Tom von Geldern, Martin Winn, Zhili Xin